Methylphenidate Sulfate Synthesis via Dimethyl Carbonate

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing methylphenidate, a psychostimulant drug, face challenges such as off-gasing of corrosive substances, limited yield, and purity issues, making them unsuitable for large-scale commercial manufacture.

Innovation Solution

A process involving the reaction of a compound with dimethylcarbonate and methanol in the presence of sulfuric acid, optimizing molar equivalents and temperatures to produce a sulfate salt of methylphenidate, while allowing for the separation and reduction of impurities, thereby improving yield and purity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If sulfonyl chloride is used for preparing methylphenidate, then the reaction can proceed, but corrosive reagents cause equipment corrosion and handling difficulties

Engineering Contradiction:
Improveease of manufactureVSAvoidcorrosion of manufacturing equipment
Core Design Contradiction:
Ease of manufactureVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters by replacing sulfonyl chloride with dimethyl carbonate as the reagent. This substitution fundamentally alters the reaction system from using a corrosive sulfonating agent to using a milder carbonating agent, thereby eliminating equipment corrosion while maintaining manufacturing feasibility.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs dimethyl carbonate, a less hazardous and more environmentally benign reagent compared to sulfonyl chloride. This reagent is easier to handle, produces fewer harmful byproducts, and does not require specialized corrosion-resistant equipment, making it suitable for large-scale commercial manufacture.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

2Productivity

If traditional esterification process is used, then methylphenidate can be produced, but the yield is limited to 70-75%

Engineering Contradiction:
ImproveyieldVSAvoidlimited yield
Core Design Contradiction:
ProductivityVSLoss of energy

Solution Approach 1:

The patent optimizes reaction parameters including the molar ratio of dimethyl carbonate to ritalinic acid (excess DMC), reaction temperature (reflux conditions), and catalyst loading (sulfuric acid amount). These parameter changes drive the equilibrium toward higher product formation, achieving yields exceeding 90%.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs a continuous reflux process where methanol solvent and dimethyl carbonate continuously circulate through the reaction system. This continuous action maintains optimal reaction conditions throughout the process, preventing stagnation and maximizing conversion efficiency to achieve high yields.

Inventive Principle:
Principle #20Continuity of useful action

3Productivity

If traditional process is used for large scale manufacture, then production can occur, but off-gasing of SO2 and HCl causes equipment corrosion

Engineering Contradiction:
Improvelarge scale production capabilityVSAvoidoff-gasing of corrosive substances
Core Design Contradiction:
ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent replaces the harmful sulfonating process that generates corrosive SO2 and HCl gases with a carbonating process using dimethyl carbonate. The byproducts of this new process are non-corrosive methanol and carbon dioxide, which can be easily vented or recycled without causing equipment corrosion, thus enabling safe large-scale production.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

4Manufacturing precision

If dimethyl carbonate and sulfuric acid are used in traditional ratios, then reaction proceeds, but yield and purity are not optimized

Engineering Contradiction:
ImprovepurityVSAvoidreaction conditions optimization
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent systematically optimizes critical parameters including the molar ratio of dimethyl carbonate to ritalinic acid (using excess DMC to drive reaction), sulfuric acid catalyst loading (optimized amount for maximum conversion), and reaction temperature (reflux conditions). These parameter changes achieve >90% purity while maintaining process simplicity suitable for commercial manufacture.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This process enhances the yield and purity of methylphenidate, making it more suitable for large-scale commercial production by avoiding corrosive reagents and improving handling and reaction efficiency.

Implementation Method 1

reacting a compound of formula (I-A) with dimethylcarbonate to form a reaction mixture... to yield the corresponding compound of formula (I-S)

Methodology Applied
Scientific EffectEsterification: Chemical Bonding

Implementation Method 2

adding sulfuric acid to the reaction mixture... wherein the sulfuric acid is present in an amount in the range of from about 1.05 to about 2.5 molar equivalents

Methodology Applied
Scientific EffectCatalysis: Catalysis

Implementation Method 3

adding methanol to the reaction mixture; wherein the methanol is present in an amount in the range of from about 0.75 to about 5.0 molar equivalents

Methodology Applied
Scientific EffectSolvation: Solvation

Data Source

PatentEP3066076B1Process for the preparation of methylphenidate and pharmaceutical salts thereof
Publication Date: 2019.03.27 NORAMCO INC
  • EP3066076B1 patent drawing
  • EP3066076B1 patent drawing
  • EP3066076B1 patent drawing

AI summary

The present invention is directed to an improved process for the preparation of methylphenidate, stereoisomer, mixture of stereoisomers and pharmaceutically acceptable salts thereof, more particularly, the sulfate and hydrochloride salts of methylphenidate, di-threo-methylphenidate and dex-methylphenidate. Methods of removing or reducing the amount of impurities from the above described process are also disclosed.